Abbott Laboratories (ABT)
NYSE: ABT · Real-Time Price · USD
93.86
+1.06 (1.14%)
At close: Apr 28, 2026, 4:00 PM EDT
93.90
+0.04 (0.04%)
After-hours: Apr 28, 2026, 7:59 PM EDT

Company Description

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide.

It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.

The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test.

In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders.

The company also provides cancer screening and diagnostic test products. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915.

Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.

Abbott Laboratories
Abbott Laboratories logo
Country United States
Founded 1888
Industry Medical Devices
Sector Healthcare
Employees 115,000
CEO Robert Ford

Contact Details

Address:
100 Abbott Park Road, Lake County
Abbott Park, Illinois 60064-6400
United States
Phone 224 667 6100
Website abbott.com

Stock Details

Ticker Symbol ABT
Exchange NYSE
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000001800
CUSIP Number 002824100
ISIN Number US0028241000
Employer ID 36-0698440
SIC Code 2834

Key Executives

Name Position
Robert B. Ford Chairman, President and Chief Executive Officer
Philip P. Boudreau Chief Financial Officer and Executive Vice President of Finance
Daniel Gesua Sive Salvadori Executive Vice President and Group President of Established Pharmaceuticals and Nutritional Products
Christopher J. Scoggins Executive Vice President of Diabetes Care
Lisa D. Earnhardt Executive Vice President and Group President of Medical Devices
Sabina Ewing Senior Vice President of Business and Technology Services and Chief Information Officer
Michael Comilla Vice President of Investor Relations.
Erica L. Battaglia Vice President and Chief Ethics and Compliance Officer
Elizabeth Cushman Executive Vice President, General Counsel and Secretary
Melissa Brotz Senior Vice President of Global Marketing and External Affairs

Latest SEC Filings

Date Type Title
Apr 27, 2026 144 Filing
Apr 27, 2026 8-K Current Report
Apr 24, 2026 S-8 Securities to be offered to employees in employee benefit plans
Apr 17, 2026 8-K Current Report
Apr 16, 2026 8-K Current Report
Mar 26, 2026 SCHEDULE 13G/A Filing
Mar 23, 2026 S-8 Securities to be offered to employees in employee benefit plans
Mar 23, 2026 8-K Current Report
Mar 13, 2026 ARS Filing
Mar 13, 2026 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material